Inflammatory Bowel Disease

CD and UC, both forms of IBD, are seen in approximately 1% of the population and are typically characterized by chronic diarrhea (with or without bleeding), abdominal pain, and weight loss. The diagnosis is based on history, physical examination, laboratory studies, and endoscopic evaluation with biopsy. EIMs may coincide with or precede IBD diagnosis. Pharmacologic treatments have markedly advanced in the past decade, resulting in improved outcomes. Chronic inflammation from IBD as well as treatments that induce immunosuppression increases rates for certain conditions, making collaboration between GI and primary care an integral part of care for the patient with IBD.

Automated summary

CD and UC, two forms of IBD, affect approximately 1% of the population and are characterized by chronic diarrhea, abdominal pain, and weight loss. The diagnosis relies on medical history, physical examination, laboratory tests, and endoscopic evaluation with biopsy. Advances in pharmacologic treatments have significantly improved outcomes, but chronic inflammation from IBD and immunosuppressive therapies raise the risk for certain conditions, necessitating collaboration between gastroenterologists and primary care providers for comprehensive patient care.